Latest Safety Testing News

Li-S Energy has marked a milestone with the production of Australia’s first lithium metal foils and expanded its footprint in the global defense sector, supported by new manufacturing capabilities and strategic partnerships.

Altech Batteries has successfully completed rigorous destructive safety tests on its Sodium-Nickel-Chloride battery technology, demonstrating exceptional resilience and intrinsic safety under extreme conditions.

Altech has detailed its Sodium Nickel Chloride (SNC) battery technology designed specifically for hazardous explosive environments, highlighting superior safety, longevity, and minimal maintenance compared to traditional battery chemistries.

Imricor Medical Systems has successfully completed a comprehensive Human Factors study for all its devices under FDA review, marking a critical milestone towards U.S. market entry. The extensive 7-month study involved 46 healthcare professionals and tested nine products, underscoring Imricor’s growing momentum in electrophysiology innovation.

BPH Global has raised $1.1 million through a private placement to expand its Indonesian seaweed operations and advance innovative R&D projects, positioning itself for growth in sustainable aquaculture and blue economy solutions.

BPH Global has completed an 18-week R&D collaboration with Singapore Polytechnic, developing two innovative green seaweed kefir beverages that combine health benefits with commercial promise.

Noxopharm Limited has successfully cleared key preclinical hurdles for its SOF-SKN™ lupus drug and expanded its Sofra™ platform collaborations, supported by fresh funding to propel upcoming clinical trials.

PYC Therapeutics has secured regulatory approval to initiate human trials of PYC-003, a novel drug candidate targeting the root cause of Polycystic Kidney Disease (PKD). Initial safety and efficacy data are expected within 2025, marking a critical step in addressing a disease affecting millions worldwide.

Noxopharm has successfully completed key in vitro safety tests for its SOF-SKN™ lupus drug, paving the way for the upcoming HERACLES Phase 1 clinical trial.